Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Mödling – page 51

863 clinical trials in Mödling, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mödling at a glance
863
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

863 trials in Mödling

Open in trial search

Malignant glioma

Not recruiting

Study of tovorafenib versus standard chemotherapy as first treatment for children with low-grade glioma with RAF gene changes

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:Day One Biopharmaceuticals Inc.

Adenocarcinoma gastric+1

Not recruiting

Study Comparing Ramucirumab with Irinotecan, Leucovorin, and 5-FU or Paclitaxel for Patients with Advanced Stomach or Gastroesophageal Cancer After Previous Chemotherapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Plasma cell myeloma

Not recruiting

Comparison of intravenous versus subcutaneous isatuximab with lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Hidradenitis

Not recruiting

Study of lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lutikizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Fabry's disease

Not recruiting

Study on Long-Term Safety of Oral Lucerastat for Adults with Fabry Disease

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lucerastat
  • Sponsor:Idorsia Pharmaceuticals Ltd.

Study on De-escalated Induction Therapy with Methotrexate, Cytarabine, Thiotepa, and Rituximab for Newly Diagnosed Primary CNS Lymphoma Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Busulfan
  • Sponsor:Klinikum Der Landeshauptstadt Stuttgart gKAöR

Study on the Effectiveness and Safety of Pegcetacoplan for Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Apellis Pharmaceuticals Inc.

B-cell lymphoma

Not recruiting

Study of Rituximab, Polatuzumab Vedotin, and Glofitamab for Untreated Aggressive B-cell Lymphoma in Patients Over 60 Not Eligible for Full R-CHOP

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Acute myeloid leukaemia+1

Not recruiting

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Enasidenib Mesilate
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study on the Effects and Safety of Buloxibutid for Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Buloxibutid
  • Sponsor:Vicore Pharma AB

Cholangiocarcinoma+1

Not recruiting

Study on Gemcitabine and Cisplatin for Patients After Surgery for Bile Duct or Gallbladder Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:University Medical Center Hamburg-Eppendorf

Ovarian cancer

Not recruiting

Study of olaparib, durvalumab and UV1 combination as maintenance treatment for patients with recurrent ovarian cancer who do not have BRCA mutations

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Alrefimotide
  • Sponsor:Nordic Society Of Gynaecological Oncology Clinical Trial Unit

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Mödling

What the registry says about research in the country

01 Diabetes & Cardiovascular Health

Clinical research focusing on Type 2 Diabetes Mellitus patients, exploring innovative approaches to prevent heart disease. The trials evaluate the effectiveness of intensive treatment using RAS-antagonists and beta-blockers compared to standard therapy.

  • Heart Disease Prevention
  • Diabetes Management
  • Cardiac Event Reduction

Studies utilize specialized biomarkers like NT-proBNP to guide treatment strategies and reduce hospitalization rates.

02 Stroke Prevention Research

Investigating advanced treatments for ischemic stroke prevention, with particular focus on patients who have experienced acute non-cardioembolic strokes or high-risk transient ischemic attacks.

  • Post-Stroke Care
  • Blood Clot Prevention
  • Antiplatelet Therapy

The research evaluates the efficacy of asundexian, an oral FXIa inhibitor, in combination with standard antiplatelet therapy.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.